FDG PET/CT in initial staging and early response to chemotherapy assessment of paediatric rhabdomyosarcomas;Apport de la TEP/TDM au 18FDG dans la stadification initiale et l'évaluation précoce de la réponse thérapeutique des rhabdomyosarcomes pédiatriques

Medecine Nucleaire

Volumn 34, Issue 12, 2010, Pages 655-663

  Eugene T ^a   Ansquer, C ^a   Oudoux, A ^a   Corradini, N ^a   Carlier, T ^a   Thomas, C ^a   Dupas, B ^a   Kraeber Bodere F ^a   Bodet Milin, C ^a  

^a HÔTEL DIEU   (France)

Author keywords

Paediatric; PET; Rhabdomyosarcoma; Staging; Therapeutic response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FOLLOW UP; HISTOLOGY; HUMAN; INFANT; INTERMETHOD COMPARISON; METASTASIS; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SCHOOL CHILD; SCINTIGRAPHY; WHOLE BODY CT;

EID: 78649927287     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mednuc.2010.10.007     Document Type: Article

References (27)

1. Flamant F., Rodary C., Rey A., et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 1998, 34:1050-1062.
2. Crist W.M., Anderson J.R., Meza J.L., et al. Intergroup rhabdomyosarcoma study-IV: results for patients with non-metastatic disease. J Clin Oncol 2001, 19:3091-3102.
3. Paulino A.C., Okcu M.F. Rhabdomyosarcoma. Curr Probl Cancer 2008, 32:7-34. [Review].
4. Crist W.M., Garnsey L., Beltangady M.S., et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol 1990, 8:443-452.
5. Pappo A.S., Anderson J.R., Crist W.M., Wharam M.D., Breitfeld P.P., Hawkins D., et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999, 17:3487-3493.
6. Breneman J.C., Lyden E., Pappo A.S., et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003, 21:78-84.
7. Crist W., Gehan E.A., Ragab A.H., et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995, 13:610-630.
8. Raney R.B., Maurer H.M., Anderson J.R., et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001, 5:9-15.
9. Dantonello T.M., Int-Veen C., Winkler P., et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol 2008, 26(3):406-413. [Erratum in: J Clin Oncol 2008;26:1911].
10. Charest M., Hickeson M., Lisbona R., et al. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 2009, 36:1944-1951.
11. Tateishi U., Hosono A., Makimoto A., et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 2009, 23(2):1551-1561.
12. Völker T., Denecke T., Steffen I., et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007, 25:5435-5441.
13. Klem M.L., Grewal R.K., Wexler L.H., et al. PETfor staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 2007, 29:9-14.
14. Evilevitch V., Weber W.A., Tap W.D., et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008, 14:715-720.
15. Nanni C., Marzola M.C., Rubello D., Fanti S. Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas. Eur J Nucl Med Mol Imaging 2009, 36:1940-1943.
16. Ye Z., Zhu J., Tian M., Zhang H., Zhan H., Zhao C., et al. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18FFDG-PET. Ann Nucl Med 2008, 22:475-480.
17. McCarville M.B., Christie R., Daw N.C., et al. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005, 184:1293-1304.
18. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
19. Franzius C., Bielack S., Flege S., et al. Prognostic significance of (18)F-FDG and (99m)Tc-methylenediphosphonate uptake in primary osteosarcoma. J Nucl Med 2002, 43:1012-1017.
20. Hawkins D.S., Schuetze S.M., Butrynski J.E., et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcomafamily of tumors. J Clin Oncol 2005, 23:8828-8834.
21. Schuetze S.M., Rubin B.P., Vernon C., et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005, 103:339-348.
22. Lucas J.D., O'Doherty M.J., Cronin B.F., et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999, 86:550-556.
23. Denecke T., Hundsdörfer P., Misch D., et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging 2010, 37:1842-1853.
24. Gallamini A., Rigacci L., Merli F., et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006, 91:475-481.
25. Schelling M., Avril N., Nährig J., et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000, 18:1689-1695.
26. Cheson B.D., Pfistner B., Juweid M.E., et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
27. Juweid M.E., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005, 23:4652-4661.